Products - Head and neck cancers | Topic | NICE

Showing 3 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma (TA1145)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 December 2026
Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC